AI-ACLD Study: Artificial Intelligence in Advanced Chronic Liver Disease (AI-ACLD)
Application of Artificial Intelligence Using Wearable Technology in Patients With Advanced Chronic Liver Disease (ACLD): a Trajectomics Approach.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Lugano、瑞士、6900
- Ente Ospedaliero Cantonale
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adults aged 18-75 years
- Diagnosis of advanced chronic liver disease (ACLD).
- Either:
- hospitalized for hepatic decompensation or acute-on-chronic liver failure (ACLF), including ascites, hepatorenal syndrome, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding, or jaundice; or
- outpatient with Child-Pugh B cirrhosis and no evidence of hepatic decompensation or ACLF at enrolment.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Inability or refusal to provide written informed consent
- Inability to wear or correctly use the Apple Watch
- Patients with hepatocellular carcinoma beyond the Milan Criteria (one lesion up to 5 cm or 3 lesions up to 3 cm in diameter)
- Presence of hepatic decompensation or ACLF
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Feasibility and accuracy of machine learning analysis of individual health data collected by wearable device.
大体时间:From enrollment to the end of the study (6 months)
|
The primary outcome is to assess the feasibility and accuracy of machine learning analysis of individual health data collected by wearable device and to describe their patterns during hospitalization due to symptoms of decompensation or ACLF and in outpatients until hospitalization due to decompensation or ACLF in patients with liver cirrhosis. Health data continuously collected through a dedicated wearable device application comprise: heart rate and heart rate variability (HR; HRV), oxygen saturation (SpO₂), ECG (QRS, PQ, PT Tpe interval), sleep quality and duration, daily step count, tremor intensity (Hz), typing speed (taps/time). The single unit of measure used to assess the feasibility of the wearable device is the usable data acquisition rate (%), defined as the percentage of monitoring data successfully collected and suitable for analysis. |
From enrollment to the end of the study (6 months)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- AI-ACLD Study
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.